US EditionPublished • loading... • Updated
Why Is RAPT Therapeutics Stock Skyrocketing Tuesday? - GSK (NYSE:GSK), Pfizer (NYSE:PFE), RAPT Therapeutics (NASDAQ:RAPT)
GSK acquires RAPT for $2.2 billion to develop ozureprubart, a long-acting anti-IgE antibody targeting food allergies affecting over 17 million in the U.S.
- On Tuesday, GSK plc agreed to acquire RAPT Therapeutics Inc. for $58.00 per share, valuing the deal at $2.2 billion and gaining global rights to ozureprubart.
- Under new CEO Luke Miels, GSK moved to acquire RAPT, with the deal aiming to accelerate pipeline development and target validated allergy biology, company statements said.
- Ozureprubart's clinical profile suggests quarterly dosing with potential injections every 12 weeks versus current anti-IgE treatment every 2 to 4 weeks, and could help about a quarter of patients ineligible for existing therapy.
- The agreement carries an estimated $1.9 billion upfront, with transactions expected to close in the first quarter of 2026, following GSK's $2.2 billion deal for RAPT Therapeutics.
- Clinical success could shift treatment options for millions, with over 17 million U.S. patients diagnosed with food allergies and more than 1.3 million at risk of severe reactions.
Insights by Ground AI
27 Articles
27 Articles
GSK Grows in Immunology, Buying Rapt Therapeutics and Food Allergy Drug in $2.2B Deal
Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair. The post GSK Grows in Immunology, Buying Rapt Therapeutics and Food Allergy Drug in $2.2B Deal appeared first on MedCity News.
The movement will strengthen the portfolio of respiratory, immunology and inflammation
·Brazil
Read Full Article
GSK plans to acquire the US biotech company RAPT Therapeutics. The UK Group offers shareholders a 65 percent premium at the final closing price.
·Düsseldorf, Germany
Read Full ArticleCoverage Details
Total News Sources27
Leaning Left1Leaning Right2Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
C 70%
R 20%
Factuality
To view factuality data please Upgrade to Premium
